Progressive multifocal leukoencephalopathy (PML) is a neurological disorder that damages the myelin that covers and protects nerves in the white matter of the brain. It is caused by the JC virus (JCV)...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on PML is limited due to its rarity and the specific populations it affects, leading to fewer systematic studies. The condition primarily occurs in individuals with severely compromised immune systems, which complicates the ability to gather comprehensive clinical data. Additionally, the lack of identified genes or specific phenotypes further contributes to the challenges in understanding and documenting this disease.
To navigate your care for PML, consider seeking a neurologist with expertise in viral infections and immunocompromised conditions. It may also be beneficial to connect with specialized centers that focus on PML or related neurological disorders. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and contribute to the understanding of PML.
Currently, there are three orphan drugs designated for PML that are in development: allogeneic JC polyomavirus-specific T-cell therapy, glycosylated recombinant human interleukin-7, and recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc). There are also five active clinical trials investigating various aspects of PML. For more information on these trials, you can visit ClinicalTrials.gov and search for 'progressive multifocal leukoencephalopathy.'
Actionable guidance for navigating care for progressive multifocal leukoencephalopathy
To navigate your care for PML, consider seeking a neurologist with expertise in viral infections and immunocompromised conditions. It may also be beneficial to connect with specialized centers that focus on PML or related neurological disorders. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and contribute to the understanding of PML.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on PML is limited due to its rarity and the specific populations it affects, leading to fewer systematic studies. The condition primarily occurs in individuals with severely compromised immune systems, which complicates the ability to gather comprehensive clinical data. Additionally, the lack of identified genes or specific phenotypes further contributes to the challenges in understanding and documenting this disease.
To navigate your care for PML, consider seeking a neurologist with expertise in viral infections and immunocompromised conditions. It may also be beneficial to connect with specialized centers that focus on PML or related neurological disorders. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and contribute to the understanding of PML.
Currently, there are three orphan drugs designated for PML that are in development: allogeneic JC polyomavirus-specific T-cell therapy, glycosylated recombinant human interleukin-7, and recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc). There are also five active clinical trials investigating various aspects of PML. For more information on these trials, you can visit ClinicalTrials.gov and search for 'progressive multifocal leukoencephalopathy.'
Actionable guidance for navigating care for progressive multifocal leukoencephalopathy
To navigate your care for PML, consider seeking a neurologist with expertise in viral infections and immunocompromised conditions. It may also be beneficial to connect with specialized centers that focus on PML or related neurological disorders. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and contribute to the understanding of PML.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on PML is limited due to its rarity and the specific populations it affects, leading to fewer systematic studies. The condition primarily occurs in individuals with severely compromised immune systems, which complicates the ability to gather comprehensive clinical data. Additionally, the lack of identified genes or specific phenotypes further contributes to the challenges in understanding and documenting this disease.
To navigate your care for PML, consider seeking a neurologist with expertise in viral infections and immunocompromised conditions. It may also be beneficial to connect with specialized centers that focus on PML or related neurological disorders. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and contribute to the understanding of PML.
Currently, there are three orphan drugs designated for PML that are in development: allogeneic JC polyomavirus-specific T-cell therapy, glycosylated recombinant human interleukin-7, and recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc). There are also five active clinical trials investigating various aspects of PML. For more information on these trials, you can visit ClinicalTrials.gov and search for 'progressive multifocal leukoencephalopathy.'
Actionable guidance for navigating care for progressive multifocal leukoencephalopathy
To navigate your care for PML, consider seeking a neurologist with expertise in viral infections and immunocompromised conditions. It may also be beneficial to connect with specialized centers that focus on PML or related neurological disorders. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as they may offer access to new therapies and contribute to the understanding of PML.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.